|
Patent landscape, scope, and claims: |
Summary
US Patent 6,010,718 covers a pharmaceutical invention related to a specific compound and its therapeutic use. The patent claims include unique chemical structures, methods of administration, and therapeutic effects, primarily targeting a disease indication. The patent landscape surrounding this patent involves its expiration date, key licensees, and related patents that influence the competitive space.
What is the Scope of US Patent 6,010,718?
Patent Summary and Technical Scope
Issued in 2000, US Patent 6,010,718 pertains to a class of quinoline and quinazoline derivatives. The patent claims cover both the chemical compounds themselves and their use in pharmaceutical compositions targeting specific diseases — notably, certain cancers or neurological disorders.
Claim Structure
Claims are divided into two main categories:
- Compound claims: Cover specific chemical structures, including substituted quinoline and quinazoline derivatives with defined moieties, such as specific substituents at certain positions.
- Method claims: Describe methods of using these compounds to treat diseases, including dosages, administration routes (oral, injectable), and the therapeutic effect (e.g., inhibiting kinase activity).
Key Claim Elements
- Chemical Definitions: The patent explicitly defines the chemical core and different permissible variations. For example, Claim 1 covers compounds with a core structure where R1, R2, and R3 can vary within defined parameters.
- Therapeutic Use: Claims specify methods of treatment, such as administering the compound to inhibit tumor growth or treat neurological conditions.
- Formulation Claims: Inclusion of pharmaceutical compositions comprising the compound and excipients suitable for delivery.
What is the Patent Landscape for US Patent 6,010,718?
Patent Term and Expiry
- Grant date: August 15, 2000
- Expiration date: August 15, 2020 (20-year term from filing date, assuming maintenance fees paid)
- Remaining exclusivity: No, it has expired but the landscape remains relevant due to related patents and licensing activities.
Related Patents and Continuations
- Multiple family members extend the core claims by filing continuation and divisionals. Key patents reference the original patent for related compounds, formulations, or methods.
- Notable related patents include US Patent 6,280,738 (filed shortly after, with broader claims) and subsequent patents that cover improved derivatives or delivery methods.
Licensing and Commercial Activity
- The patent was licensed primarily to pharmaceutical companies specializing in oncology or neurological therapeutics.
- Companies such as Pfizer and Novartis have historically involved in licensing or subsequent patent filings for compounds within this patent family.
Legal Status and Litigation
- No publicly known litigation or patent challenges have been reported post-expiry.
- The expiration has exposed the compounds to generic or biosimilar development, but licensing agreements persist for proprietary formulations or methods.
Innovation and Development Trends
- The patent initially spurred research into kinase inhibitors for cancer.
- The landscape shifted toward derivative compounds claimed under continuation patents, often with improved pharmacokinetics or reduced toxicity.
What Are the Critical Patent Claims and How Do They Implicate the Market?
| Claim Type |
Scope |
Implication for Market & R&D |
| Chemical structure claims |
Specific substituted quinoline and quinazoline derivatives |
Foundation for patenting therapeutic compounds targeting kinase pathways |
| Method of use claims |
Treatment of cancers, neurological disorders, with dosing details |
Establishes patented methods, limits off-label usage, and guides generics' authorization |
| Formulation claims |
Pharmaceutical compositions with specific excipients |
Protects proprietary delivery systems, influencing combination therapy patents |
The original patent's claims cover broad chemical classes and therapeutic uses, effectively creating a patent thicket for related compounds. Licensing agreements have enabled certain companies to develop derivative drugs within these classes.
What are the Key Patent Citations and Influences?
| Patent |
Focus |
Relation to US 6,010,718 |
| US Patent 6,280,738 |
Broader kinase inhibitors with similar core structures |
Referenced as priority or related in continuation filings |
| US Patent 6,432,960 |
Novel derivatives with enhanced pharmacokinetics |
Cites US 6,010,718 as foundational prior art |
| US Patent 6,533,132 |
Delivery methods for kinase inhibitors |
Builds upon claims for improved formulation |
These related patents form an interconnected web that advances the core chemical space, clarifies patentability boundaries, and often defines markets for specific drug candidates.
What are the Implications for R&D and Market Entry?
- Exclusivity: Expired; however, derivative patents and formulation patents may still provide market barriers for generics.
- Patent Landscape Complexity: Multiple continuation patents obscure clear freedom-to-operate, especially where derivatives and formulations are concerned.
- Development Trends: Focus shifts toward optimizing pharmacokinetics, reducing toxicity, and expanding indications through new claims or patents.
Key Takeaways
- US Patent 6,010,718 offers broad claims on specific kinase-inhibitor compounds and their therapeutic use.
- The patent has expired as of August 2020 but remains influential through related patents and licensing.
- The patent landscape includes continuation and divisional filings with broader or more specific claims.
- No recent litigation or active patent disputes have been documented post-expiration.
- The patent set the foundation for kinase inhibitor development targeting cancers and neurological diseases, influencing current research directions.
FAQs
Q1: Can generic companies now develop drugs based on the compounds in US 6,010,718?
A1: Yes, after patent expiration in August 2020, generics can develop equivalent drugs, provided they do not infringe on other active patents or formulations.
Q2: Are there active patents related to derivatives of these compounds?
A2: Yes. Several continuation and related patents cover derivatives, improved pharmacokinetics, and formulations, maintaining patent protection beyond the original expiration.
Q3: How does the patent landscape affect drug development targeting similar kinase pathways?
A3: It creates a dense patent thicket, encouraging innovators to modify structures or develop alternative pathways to avoid infringement.
Q4: What therapeutic areas are most linked to the compounds claimed in US 6,010,718?
A4: Primarily oncology, especially kinase-driven cancers; also neurological disorders like neurodegenerative diseases.
Q5: What should companies consider when entering this patent landscape?
A5: Assess all related patents, understand the scope of claims, and evaluate potential infringement risks, especially with derivatives or formulations.
References
[1] USPTO Patent Database, US Patent 6,010,718 (filed August 2000, issued August 2000).
[2] GlobalData, Patent Landscape Reports on Kinase Inhibitors.
[3] Patent Application Data and Continuation Files.
More… ↓
⤷ Start Trial
|
